GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » Other Liabilities for Insurance Companies

Genmab A/S (Genmab A/S) Other Liabilities for Insurance Companies


View and export this data going back to . Start your Free Trial

What is Genmab A/S Other Liabilities for Insurance Companies?

Other Liabilities for Insurance Companies only applies to insurance companies.


Genmab A/S (Genmab A/S) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » Other Liabilities for Insurance Companies
Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.